Darzalex (daratumumab) is a human IgG1k monoclonal antibody targeting CD38 on multiple myeloma cells. It is the backbone of multiple myeloma therapy across all treatment lines, from newly diagnosed to relapsed/refractory.
Darzalex binds CD38 on myeloma cells, inducing death through CDC, ADCC, ADCP, and direct apoptosis. Also depletes immunosuppressive regulatory T and B cells.
Annual revenue trajectory
Revenue of competing drugs in the same class
4 indications
All approved therapeutic uses
Darzalex is the backbone of MM therapy, used in >70% of regimens across all lines. Subcutaneous formulation (5-min vs 7-hr IV) dramatically improved convenience. Direct competitor Sarclisa has minimal share.
Projected to reach $12B+ by 2027, driven by earlier treatment lines (smoldering MM), SC adoption, and geographic expansion. J&J also developing bispecifics (teclistamab) to complement the franchise.
| Drug | Company | Revenue |
|---|---|---|
| Revlimid (lenalidomide) | BMS | $6.0B (declining) |
| Pomalyst (pomalidomide) | BMS | $3.5B |
| Kyprolis (carfilzomib) | Amgen | $2.0B |
| Sarclisa (isatuximab) | Sanofi | $0.4B |
Revenue figures from company annual reports (FY2023). Clinical trial data from ClinicalTrials.gov. Competitive intelligence from Evaluate Pharma World Preview 2024 and IQVIA MIDAS. Market analysis by Medifirm Intelledge Global.